Related Experiment Video
Updated: Aug 10, 2025
08:27
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
7.7K
Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
C Alex Wiles1, Nisha B Shah2, Jake Bell2
1Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Crohn'S & Colitis 360
|February 13, 2023
Summary
Medication adherence to tofacitinib was high in patients with severe ulcerative colitis and Crohn's disease, even after prior biologic failure. This supports its use in refractory inflammatory bowel disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Tofacitinib is approved for ulcerative colitis and studied in Crohn's disease.
- Understanding oral medication adherence in severe inflammatory bowel disease (IBD) is crucial.
Purpose of the Study:
- To evaluate medication adherence and real-world outcomes of tofacitinib in IBD patients.
- To assess adherence in a cohort with highly refractory disease.
Main Methods:
- Retrospective review of IBD patients initiating tofacitinib at a single center.
- Adherence measured by proportion of days covered (PDC).
Main Results:
- Sixty-three patients with IBD were included, all with prior biologic failure.
- Mean PDC was 95.7% for ulcerative colitis and 93.1% for Crohn's disease.
- Significant clinical and endoscopic responses were observed.
Conclusions:
- High medication adherence to tofacitinib was observed in this cohort of refractory IBD patients.
- Tofacitinib demonstrates promising adherence and outcomes in severe, treatment-resistant IBD.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
204
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
227
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
227
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
180
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
180
01:30Inflammatory Bowel Disease II: Crohn's Disease
332
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
332
01:29Drugs for Treatment of Ulcerative Colitis in IBD
211
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
211